Q1 2026 Supriya Lifescience Ltd Earnings Call Transcript
Key Points
- Supriya Lifescience Ltd (BOM:543434) reported a strong EBITDA margin of 36% for Q1 FY26, despite a 10% decline in revenue.
- The company's backward integration improved significantly, rising to 81% from 69% in Q1 FY25, enhancing control over key inputs and reducing dependence on external sources.
- The European market share increased from 36% in Q1 FY25 to 41% in Q1 FY26, indicating strong growth in this region.
- Supriya Lifescience Ltd (BOM:543434) is on track to achieve its goal of INR1,000 crores in revenue by FY27, supported by a strong pipeline and planned product launches.
- The company has started validation campaigns at its Ambernath site, which will contribute to its CDMO strategy, with commercial contributions expected from Q4 of this year.
- Revenue for the quarter declined by 10% year-on-year to INR145 crores, primarily due to delays in production facility campaigns following repair and maintenance work.
- EBITDA decreased by 17% year-on-year to INR52 crores, reflecting the impact of reduced revenue.
- The company faced production delays due to maintenance activities at its Lote Parshuram facility, affecting sales in Q1.
- There is uncertainty regarding the US tariff situation, which could potentially impact future revenue, although the current impact is minimal.
- The capacity utilization rate, although improved, is still not fully optimized, with older blocks requiring further debottlenecking and automation.
Ladies and gentlemen, good day, and welcome to Supriya Lifescience Limited Q1 FY26 Earnings Conference Call. (Operator Instructions) Please note that this conference is being recorded. I now hand the conference over to Ms. Sneha Salian.
Thank you, and over to you, ma'am.
Thank you, Shubham. Good morning, everyone. On behalf of Supriya Lifescience Limited, I extend a warm welcome to all participants for the Q1 FY26 financial results discussion. Today on the call, we have Dr. Satish Wagh, Executive Chairman and Whole-Time Director; Dr. Saloni Wagh, Managing Director; and Mr. Krishna Raghunathan, Chief Financial Officer.
Before we begin the call, I would like to give a short disclaimer. This call may contain some of the forward-looking statements, which are completely based upon our belief, opinion and expectations as of today. These statements are not a guarantee of our future performance and involve unforeseen risks and uncertainties.
With this, I would like to hand over the call to Mr. Krishna Raghunathan for
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
